Anti-Human CD19 Monoclonal Antibodies

PA007510.m1: In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody, Mouse IgG1 Kappa (Clone: 4G7)

Recombinant mouse IgG1 Monoclonal Antibody. 
Clone: 4G7.
Isotype: Mouse IgG1 kappa.
Source: The anti-human CD19 monoclonal antibody (clone: 4G7) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 4G7) specifically binds to the human CD19 protein.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD19 protein. 
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

The 4G7 antibody binds to the human CD19 protein, a transmembrane protein expressed in all B lineage cells including human plasma cells. CD19 plays two major roles in human B cells: it acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane, and works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies.

References of Anti-human CD19 Monoclonal Antibody:

Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.
Poirot, L., et al. Cancer Res. 2015 Sep 15;75(18):3853-64. doi: 10.1158/0008-5472.CAN-14-3321. PMID: 26183927
We provide proof of concept for the general application of this approach by manufacturing a TCR/CD52-deficient CD19 CAR T cell (dKO-CART19). ...We demonstrate that this product does not mediate alloreactivity and that it can be selectively engrafted in the presence of alemtuzumab, while maintaining antitumor activity indistinguishable from standard CD19 CAR T cells in an orthotopic CD19+ lymphoma murine model. ...CD19 CARs were cloned into a commercial lentiviral vector backbone downstream from an EF1α promoter and concentrated lentiviral vectors were produced by Vectalys. ...Furthermore, the antitumor activity of TCR-deficient T cells was not compromised, as CD19 CAR-transduced TCR-deficient T cells exhibited antitumor activity indistinguishable from standard CD19 CAR T cells in anorthotopic human CD19+ Raji-ffluc lymphoma model in NSG immunodeficient mice. ...The same was true when using other cellular targets, that is, SupT1 cells engineered to express CD19 compared with control parental SupT1 cells (not shown).
Tags: anti-human CD19; anti-human CD19 4G7 mAb

Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma.
Smeltzer, J. P., et al. Clin Cancer Res. 2014 Jun 1;20(11):2862-72. doi: 10.1158/1078-0432.CCR-13-2367. PMID: 24727328
To differentiate different PD1+ cells such as exhausted effector T cells and T follicular helper cells (TFH) cells, PD1+ cells were costained with CD3, CD19, CXCR5, and TIM3. ...CD19+ cells were isolated from lymphoma samples by positive selection and cultured with FDCs at a ratio of 2.5:1. At 48 hours, viability of CD19+ cells was determined by the percentage of B cells that were negative by flow cytometry for Annexin V and propidium iodide. ...To further analyze other markers of coexpression, flow cytometry was performed on follicular lymphoma samples with antibodies to CD3, CD19, and PD1. ...The presence of FDC was associated with significant increase in viability of CD19+ cells (P = 0.003). B, sequential biopsies from diagnosis to transformation from two representative patient samples demonstrate a transition from PD1+ cells in the follicle to a diffuse pattern as patient nears transformation. ...Cells were stained with fluorochrome-conjugated antibodies to human ICAM (R&D Systems; clone BBIG-l1), CD3 (clone HIT3a), CD19 (clone 4G7), PD1 (clone EH12.1), CD14 (clone M5E2), CD163 (clone GH1/61), CD21 (clone B-ly4), CD273 (clone M1H18), CD274 (clone M1H1), TIM3 (clone 344823), and CD23 (clone EBVCS-5; all obtained from BD Biosciences) and analyzed by flow cytometry and the data were analyzed using CellQuest software (Becton Dickinson).
Tags: anti-human CD19 4G7 antibody in cancer research; anti-human CD19 4G7 antibody in vivo

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton, H. M., et al. Cancer Res. 2008 Oct 1;68(19):8049-57. doi: 10.1158/0008-5472.CAN-08-2268. PMID: 18829563
CD19 is a 95-kDa transmembrane glycoprotein of the immunoglobulin superfamily containing two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. ...CD19 is an attractive target for cancers of lymphoid origin due to its high expression in most non–Hodgkin's lymphomas (NHL) and many leukemias, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and hairy cell leukemia (HCL; refs. 2, 3). ...Thus, anti-CD19 antibodies may be efficacious against early B-cell malignancies such as ALL or other CD20− tumors, which are not amenable to treatment with rituximab, and as salvage regimens for patients failing rituximab. ...CD19 has been a focus of immunotherapy development for over 20 years, and several CD19-specific antibodies have been evaluated for the treatment of B-lineage malignancies in vitro, in mouse models, and in clinical trials. ...These clinical studies as well as trials with anti-CD19 immunoconjugates have validated CD19 as a target for B-cell malignancies, and the results with bispecific antibodies indicate that enhancing the engagement of immune effector functions may improve therapeutic efficacy.
Tags: anti-human CD19 4G7 mAb in human tumor model; bioactivity of anti-human CD19 4G7 mAb

For more references about Anti-human CD19 Monoclonal Antibody please contact our scientific support team with message@sydlabs.com.

Syd Labs provides the following in vivo grade recombinant anti-mouse CD19 monoclonal antibodies:
Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3)

Syd Labs provides the following in vivo grade recombinant anti-human CD19 monoclonal antibodies:
Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1)
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43)
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63)

Syd Labs provides the following recombinant anti-mouse CD19 monoclonal antibodies for flow cytometry:
Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3) for flow cytometry

Syd Labs provides the following recombinant anti-human CD19 monoclonal antibodies for flow cytometry:
Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43) for flow cytometry